PHARMACY

Zipnosis brings services to Colorado, Washington

BY Allison Cerra

ST. PAUL, Minn — A provider of simple and convenient online diagnosis and treatment of common health needs is broadening its reach.

Zipnosis said it will launch services in Colorado and Washington on May 15. Patients interested in having their symptoms reviewed and diagnosed can register at Zipnosis.com.

How it works: Patients first spend a few minutes answering questions using the company’s adaptive online interview. The information then is converted into a fully digital note and securely sent to a board-certified and licensed clinician within their state. From 8 a.m. to 8 p.m., the clinician responds in an hour with a diagnosis and treatment plan, including a prescription, if clinically appropriate. If a patient completes the online survey outside of normal hours, it will be reviewed as soon as the clinic opens in the morning.

Clinicians may diagnose such common health needs as colds, flu, sinus infections, cold/canker sores, seasonal allergies, acne and tobacco cessation, as well as female bladder infections and yeast infections. The service costs $25.

"We’re excited to offer Colorado and Washington state residents access to the most affordable and convenient health care in America," said Zipnosis CEO and co-founder Jon Pearce. "Our online diagnosis reduces access and payment barriers, while ensuring a safe, appropriate diagnosis in minutes."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Alkermes to buy Elan Drug Technologies

BY Alaric DeArment

WALTHAM, Mass. — Alkermes will buy Irish drug maker Elan’s drug formulation and manufacturing business for $960 million, the two companies said Monday.

Alkermes will buy Elan Drug Technologies and incorporate the combined company in Ireland, naming it Alkermes PLC. Alkermes said the acquisition would give it an edge in treating central nervous system disorders and expected to have diverse revenue streams from 25 commercialized drugs.

“The merger will be financially transformative and create a profitable, global biopharmaceutical company with a diversified CNS product portfolio and a strong foundation for growth,” Alkermes CEO Richard Pops said. “Both companies have a proven track record as innovators.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Study: Allergy rhinitis symptoms linked to sleep disruption

BY Alaric DeArment

HORSHAM, Pa. — Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

The survey, the "Nasal Allergy Survey Assessing Limitiations 2010," was timed to coincide with National Asthma and Allergy Awareness Month. The survey found that people with nasal allergy symptoms — which peak during the spring months, particularly April and May, and include repeated sneezing, post-nasal drip, nasal congestion and headache — often experience such sleep disturbances as difficulty falling asleep and waking up during the night.

Results of NASL 2010 suggested that the fatigue nasal allergy patients experience may be related to disruption of sleep, which also may lead to their feeling irritable and “miserable.” The survey’s results were recently presented at the American Academy of Allergy, Asthma and Immunology’s annual meeting in San Francisco.

“The negative impact that allergic rhinitis symptoms can have on a patient’s quality of sleep is considerable, as it not only affects them physically but also emotionally,” Gary Gross of the Dallas Allergy & Asthma Center said on behalf of Teva. “As allergy season is upon us, it’s important for patients suffering from allergic rhinitis symptoms like post-nasal drip to understand how these symptoms can negatively affect their quality of life.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES